Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases

IF 1.4 Q3 SURGERY
Peter Harald Cashin MD, PhD , Dan Asplund MD, PhD , Elinor Bexe Lindskog MD, PhD , Lana Ghanipour MD, PhD , Ingvar Syk MD, PhD , Wilhelm Graf MD, PhD , Per J. Nilsson MD, PhD , Gabriella Jansson Palmer MD, PhD
{"title":"Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal peritoneal metastases","authors":"Peter Harald Cashin MD, PhD ,&nbsp;Dan Asplund MD, PhD ,&nbsp;Elinor Bexe Lindskog MD, PhD ,&nbsp;Lana Ghanipour MD, PhD ,&nbsp;Ingvar Syk MD, PhD ,&nbsp;Wilhelm Graf MD, PhD ,&nbsp;Per J. Nilsson MD, PhD ,&nbsp;Gabriella Jansson Palmer MD, PhD","doi":"10.1016/j.sopen.2024.05.018","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated.</p></div><div><h3>Objectives</h3><p>To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease.</p></div><div><h3>Methods</h3><p>Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated.</p></div><div><h3>Results</h3><p>Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (<em>n</em> = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30–58) in the interventional group and 19 months (95%CI: 15–24) in the palliative group (HR 0.35 95%CI: 0.20–0.63, <em>p</em> = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (<em>n</em> = 575) was 41 months (95%CI: 38–45).</p></div><div><h3>Conclusion</h3><p>After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.</p></div>","PeriodicalId":74892,"journal":{"name":"Surgery open science","volume":"20 ","pages":"Pages 45-50"},"PeriodicalIF":1.4000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589845024000848/pdfft?md5=7283d17e1269114b08224a2bce659265&pid=1-s2.0-S2589845024000848-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery open science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589845024000848","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Secondary treatment of recurrent colorectal peritoneal metastases after previous cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly investigated.

Objectives

To evaluate the overall survival outcome of secondary (repeat) CRS + HIPEC compared to palliative treatment in recurrent peritoneal disease.

Methods

Patients with colorectal peritoneal metastases treated with an index CRS + HIPEC and subsequently having recurrent peritoneal disease were identified from the prospective Swedish national HIPEC registry. Patients were divided into interventional group (secondary CRS + HIPEC) or palliative group. Multivariable logistic regression, propensity-score matching, and survival outcomes were calculated.

Results

Among 575 patients who underwent complete CRS between 2010 and 2021, 208 (36 %) were diagnosed with a subsequent recurrent peritoneal disease. Forty-two patients (20 %) were offered secondary CRS + HIPEC. Propensity-score matching of secondary interventional cases with palliative cases succeeded in 88 % (n = 37) in which female sex, lower peritoneal cancer index at index surgery, longer disease-free interval, and absence of extra-peritoneal metastases were identified as the most relevant matching covariates. Median OS from date of recurrence was 38 months (95%CI 30–58) in the interventional group and 19 months (95%CI: 15–24) in the palliative group (HR 0.35 95%CI: 0.20–0.63, p = 0.0004). Sensitivity analyses confirmed the results. As reference, the median OS from index CRS + HIPEC in the whole colorectal registry (n = 575) was 41 months (95%CI: 38–45).

Conclusion

After matching for relevant factors, the hazard ratio for death was significantly reduced in patients who were offered a secondary CRS + HIPEC procedure for recurrent peritoneal disease. Selection bias is inherent, but survival outcomes were comparable to those achieved after the initial procedure.

复发性结直肠腹膜转移瘤的二次细胞剥脱手术和腹腔内热化疗
背景对既往接受过囊肿切除手术(CRS)和腹腔内热化疗(HIPEC)后复发的结直肠腹膜转移瘤进行二次治疗的研究很少。目的评估复发性腹膜疾病二次(重复)CRS + HIPEC与姑息治疗相比的总体生存结果。方法从瑞典全国前瞻性 HIPEC 登记中识别出接受过一次 CRS + HIPEC 治疗后腹膜疾病复发的结直肠腹膜转移患者。患者被分为介入组(二次 CRS + HIPEC)或姑息组。结果在2010年至2021年期间接受完全CRS的575名患者中,有208人(36%)被诊断出随后复发腹膜疾病。42名患者(20%)接受了二次CRS+HIPEC治疗。二次介入病例与姑息病例的倾向分数匹配成功率为88%(n = 37),其中女性性别、指数手术时腹膜癌指数较低、无病间隔时间较长以及无腹膜外转移被确定为最相关的匹配协变量。介入组从复发之日起的中位生存期为38个月(95%CI:30-58),姑息组为19个月(95%CI:15-24)(HR 0.35 95%CI:0.20-0.63,P = 0.0004)。敏感性分析证实了上述结果。作为参考,在整个结直肠登记(n = 575)中,指数 CRS + HIPEC 的中位 OS 为 41 个月(95%CI:38-45)。选择偏差是固有的,但生存结果与初次手术后的结果相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
审稿时长
66 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信